Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NEW YORK, Feb. 17, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Innocoll Holdings plc (NASDAQ:INNL) securities between November 3, 2016 through December 29, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/innocoll-holdings-plc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/innocoll-holdings-plc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
